NEW

Pre-eclampsia Screening Antenatal Bloods from 20 weeks

Pre-eclampsia is a serious complication in pregnancy which affects both the mother and unborn child. It is defined as pregnancy-induced hypertension and proteinuria. It is well recognised, and is a major cause of maternal, fetal and neonatal morbidity and mortality. The disorder develops early in the first trimester. Pre-eclampsia and eclampsia may occur in as many as 8% of pregnancies and the most recent official report from the UK Centre for Maternal and Child Enquiries (CMACE 2011) ranked PE as the second most common direct cause of maternal death, accounting for around 18% of direct maternal deaths between 2006-2008.
This screening test allows for targeted perinatal care, risk stratification and clinical benefit for earlier management of pre-eclampsia.
Placental Growth Factor (PlGF) is the most discriminating biochemical marker for pre-eclampsia and especially for early onset pre-eclampsia. Levels of sFIT-1/PIGF are determined in parallel and the sFlt-1/PIGF ratio are calculated. The ratio has been shown to be a better predictor of PE than either measure alone. The Roche sFlt-1/PIGF ratio allow for confirmation of pre-eclampsia with a sensitivity of 82% and a specificity of 95% at a cut-off of 85. This assay is validated for pre-eclampsia testing from 20 weeks gestation.

 

Test Code Sample Type Turnaround Time
Pre-Eclampsia Screen PET B  1 day